Cookies?
Library Header Image
LSE Research Online LSE Library Services

HTA69 A retrospective analysis of the Italian Medicines Agency’s evaluation of real-world evidence in innovativeness assessments

Civitelli, Diego ORCID: 0009-0002-9398-8857, Mills, Mackenzie and Kanavos, Panos ORCID: 0000-0001-9518-3089 (2025) HTA69 A retrospective analysis of the Italian Medicines Agency’s evaluation of real-world evidence in innovativeness assessments. Value in Health, 28 (6, Supplement 1). S259. ISSN 1098-3015

Full text not available from this repository.
Identification Number: 10.1016/j.jval.2025.04.1080

Abstract

The Italian Medicines Agency (AIFA) assesses the innovativeness of drugs based on unmet need, added clinical benefit, and quality of evidence. The designation provides access to the 1 billion euro Innovative MedicinesFundand faster market access. We investigate the use of Real-World Evidence (RWE) in submissions for innovative status and their appraisal by AIFA.

Item Type: Article
Additional Information: © 2025 Published by Elsevier Inc.
Divisions: LSE Health
Health Policy
Subjects: R Medicine > RA Public aspects of medicine
R Medicine > RS Pharmacy and materia medica
Date Deposited: 17 Jul 2025 10:18
Last Modified: 17 Jul 2025 10:18
URI: http://eprints.lse.ac.uk/id/eprint/128858

Actions (login required)

View Item View Item